The Inflation Reduction Act (IRA) is a sneaky piece of legislation. It sounds so promising with a cap on out-of-pocket (OOP) spending in Part D and really sticking it to Big Pharma. But does the legislation get us to the stated goal of lower drug prices and have outcomes (or consequences) that are worth the…
Caught my eye… a weekly catch-all of stuff that I found important. Obviously big news this week was the release of the Medicare drug negotiation lists for 2026. I wrote about it and, I also appreciated Scott Gottlieb’s tweets (Xs?) on it If not this, then what? GOP plans for healthcare: AstraZeneca’s suit against the…
Yesterday the Centers for Medicare & Medicaid Services (CMS) released the list of drugs that they have selected as part of the initial year of Medicare drug price negotiation under the Inflation Reduction Act (IRA). These drugs will be negotiated over the next year with implementation of the prices to begin in 2026. And there…
The 2026 list of Medicare negotiated drugs came out this morning and it’s a mad dash to dig in and get some sense of where this program might go. I imagine some companies (hi Astellas) are breathing a sigh of relief and others are glad they didn’t get hit worse. I found the information released…
On Tuesday we are expecting to learn what are the first drugs that will be negotiated as part of the Inflation Reduction Act’s (IRA’s) 2026 Medicare negotiation program. I use the word negotiated loosely. Last fall I did a lot of work looking at Part D spending files and patent expiration dates and expectations for…